| __timestamp | HUTCHMED (China) Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 17293000 |
| Thursday, January 1, 2015 | 110777000 | 26470000 |
| Friday, January 1, 2016 | 156328000 | 28307000 |
| Sunday, January 1, 2017 | 175820000 | 30354000 |
| Monday, January 1, 2018 | 143944000 | 32160000 |
| Tuesday, January 1, 2019 | 160152000 | 37571000 |
| Wednesday, January 1, 2020 | 188519000 | 39951000 |
| Friday, January 1, 2021 | 258234000 | 50159000 |
| Saturday, January 1, 2022 | 311103000 | 54577000 |
| Sunday, January 1, 2023 | 384447000 | 61940000 |
Unleashing insights
In the ever-evolving landscape of the biotechnology and pharmaceutical sectors, understanding cost dynamics is crucial. Over the past decade, HUTCHMED (China) Limited and Vericel Corporation have showcased contrasting trends in their cost of revenue. From 2014 to 2023, HUTCHMED's cost of revenue surged by over 430%, reflecting its aggressive expansion and scaling efforts in the Asian markets. In contrast, Vericel Corporation, focusing on regenerative medicine, saw a more modest increase of approximately 260% during the same period. This divergence highlights the strategic differences between the two companies, with HUTCHMED investing heavily in growth, while Vericel maintains a steady, sustainable approach. As we look to the future, these trends offer valuable insights into the operational strategies and market positioning of these industry players.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Vericel Corporation
Bristol-Myers Squibb Company vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Zoetis Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost of Revenue Comparison: BeiGene, Ltd. vs Vericel Corporation
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and HUTCHMED (China) Limited
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Veracyte, Inc. and Vericel Corporation's Expenses
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.